September 8th 2024
Investigators analyzed levels of CXCL10, MMP3, S100A8, ACP5, and CCL2 in patients treated with biologics and methotrexate.
September 7th 2024
September 7th 2024
September 4th 2024
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Moving Beyond the Joint: The Interplay between Gout and Kidney Disease
September 6th 2024Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.
New Insight: A Look at Corneal Transplant Alternatives w/ John Sheets, PhD
September 5th 2024Host Veeral Sheth, MD is joined by John Sheets, PhD, the president, CEO, and co-founder of Pantheon Vision, an early research-stage organization working to develop bioengineered solutions to eliminate corneal blindness.
Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
September 5th 2024Panelists discuss how head-to-head clinical trial data shape their treatment decisions, the significance of consistent remission rates across different patient populations, and the frequency with which remission data influence their choices to switch therapies.
Advanced Treatment Options for RA: Exploring the Data
September 5th 2024Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).